Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review

Gebremicheal Gebreslassie Kasahun1
Gebre Teklemariam Demoz2
Desilu Mahari Desta3

1Pharmacoepidemiology and Social Pharmacy Unit, School of Pharmacy, College of Health Science, Aksum University, Aksum, Ethiopia; 2Clinical Pharmacy Unit, School of Pharmacy, College of Health Science, Aksum University, Aksum, Ethiopia; 3Clinical Pharmacy Unit, School of Pharmacy, College of Health Science, Mekelle University, Mekelle, Ethiopia

Background: Helicobacter pylori is a spiral-shaped gram-negative bacteria which colonize the gastric or intestinal mucosa of humans and induce histologic inflammation. It is associated with peptic ulcer, gastritis and cancer. The infection of H. pylori remains a prevalent and worldwide chronic disease. It causes more than 90% and 80% of duodenal and gastric ulcers, respectively. This shows the world population is highly infected with H. pylori. About one-third of the adult population residing in Northern Europe and Northern America were found infected with H. pylori. Moreover, above 50% of population living in Southern and Eastern continents are infected with H. pylori. The global burden and occurrence of H. pylori infection remains prevalent and worldwide. Despite this, the trend of the bacterial resistance is not recently studied which can help in the adoption of global, regional and local prevention strategies.

Objective: The aim of the study was to systematically review the existing published literature that presents the estimate of H. pylori antibiotic resistance.

Methods: A protocol was primarily registered in PROSPERO International prospective register of systematic reviews and has given a registration number CRD42017068710. It was registered after checking whether there was similar study being conducted. A database search (PubMed/Medline and Google scholar) was used to collect relevant articles. A standardized form was prepared for the extraction of relevant data from studies which fulfilled the eligibility criteria. A National Institute for Health research (NIH)-based quality assessment tool was utilized to assess the quality of studies included in the study.

Results: Our searching process has retrieved a total of 288 publications which later resulted in 38 articles for full-text review. Among the 38 articles reviewed in full text, 14 studies were included which fulfilled the inclusion criteria. H. pylori-pooled overall prevalence rate of antibiotic resistance was found to be 4.55% (95% confidence interval (CI): 3.96–5.22%) to amoxicillin, 27.22% (95% CI: 25.89–28.58%) to clarithromycin, 39.66% (95% CI: 38.20–41.15%) to metronidazole, and 22.48% (95% CI: 21.24–23.76%) to levofloxacin.

Conclusion: The primary antibiotic resistance pattern of H. pylori is increasing worldwide. Thus, implementation of local drug susceptibility surveillance program, rational prescribing and use of antibiotics are necessary.

Keywords: H. pylori, primary antibiotics resistance, drug resistance, systematic review
Europe, South America and Asia were infected with *H. pylori*. This was over pronounced in immigrants coming from countries with higher prevalence of *H. pylori*.5

Worldwide, various eradication strategies are proposed for the treatment of *H. pylori* infection including triple therapy, sequential therapy, concomitant therapy, quadruple therapy and hybrid therapy.6,7 The Maastricht IV Florence Consensus report overemphasized, eradication of *H. pylori* infection produces a long-term relief of dyspepsia. However, a long-term treatment with proton pump inhibitors is associated with the development of a corpus-predominant gastritis which accelerates to the development of atrophic gastritis.8

Antibiotic resistance is nowadays the challenging issue in the treatment of bacterial infections. It is still continuing as global public health threat specifically in most of the major microbial pathogens.9,10 Similar to other bacterial resistances, *H. pylori* drug resistance is also the main factor affecting the efficacy of current treatment regimes.11 Various resistance mechanisms are described earlier however, point mutation on the surface of bacterial chromosome is described as the main causes of treatment failure due to drug resistance.12

*H. pylori* resistance to antibiotics is the major cause of treatment failure.13 Patients with sensitive isolates of clarithromycin (CLR) isolates have shown 100% eradication compared to none of patients with CLR resistant isolates.14 This indicates CLR resistance was responsible for the treatment failure. In addition to this, there are different mechanisms of resistance the bacteria can remain unharmed. These includes redox intracellular potential, pump efflux systems and membrane permeability for medications including to CLR, metronidazole (MTR), Quinolones, amoxicillin (AMX) and tetracycline.15 Prolonged hospitalization and use of antibiotics without prescription were also indicated as major reasons for the increased incidence of bacterial resistance.16

In vitro antibiotic susceptibility tests of *H. pylori* need standard culture because it is a relatively fastidious and slow-growing microaerophilic microorganism.17 Antibiotic susceptibility test helps in the proper prescribing and use of medications, and increase patient treatment outcome. Despite this, the trend of bacterial resistance is not yet recently studied which helps in the adoption of appropriate global and regional prevention strategies. Therefore, the purpose of this review was to systematically review and analyze existing published literature that presents estimates of primary antibiotic resistance of *H. pylori* in adult population.

**Methods**

**Search Strategy**

Before beginning of the study, the recent publication of the research question was checked to prevent over duplication in PROSPERO International prospective register of systematic reviews and had registered with a registration number; CRD42017068710. A comprehensive systematic search was done using searching key terms; *H. pylori* antibiotic resistance, amoxicillin, clarithromycin, metronidazole, and levofloxacin adding Boolean terms OR, AND, and NOT to gather relevant articles of a consecutive three years (2015 to 2017). A search engines; PubMed/Medline and Google scholar were used to collect relevant literature (Supp 1 record identification).

**Eligibility Criteria**

Studies conducted in adult age group greater than eighteen, bacteria confirmed on endoscopic observation/diagnosis from gastric/duodenal biopsy, previously never taken *H. pylori* treatment, *H. pylori* infection without gastric/duodenal cancer, had no prior 2-weeks history of acid secretion inhibitors drug intake (proton pump inhibitors or H2-blockers), had not undergone gastric surgery and published in English language between 2015 and 2017 were the eligibility criteria for inclusion in the study.

**Selection and Extraction of Data**

Data were extracted using a standardized pre-prepared table to collect similar evidence from each literature. The evidence extracted includes: author/s name and year of the study, study area or country, number of study participants, study period and prevalence estimate of antibiotic resistance. This was based on the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement for reporting systematic reviews and meta-analyses of studies flow chart (Figure 1).18

**Statistical Analysis**

An initial extraction and estimation of pooled prevalence using Wilson method of double arcsine transformations were done to estimate a confidence interval for a proportion of studies in Excel.19 A pooled overall prevalence rate was estimated with 95% confidence interval (CI). This was interpreted and compared among countries and continents.

**Quality Assessment**

Two reviewers (GGK and GTD) carried out the initial screening of the citations retrieved in the searches based
on titles and abstracts followed by a full-text assessment of any article identified as being potentially eligible. Any discrepancies during the assessment had resolved by the team. Both reviewers have made a methodological quality assessment on the included eligible studies. The National Institute for Health research (NIH) based Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies was used to assess the methodological quality of studies included in the systematic review rating; good = 2, fair = 1 and poor (cannot be determined, not reported or not applicable) = 0.20

Results

Search results

Our searching process has retrieved a total of 288 publications which later resulted in 38 articles for full-text review. Among 38 articles reviewed in full text, 14 studies have been included for the study which fulfilled the inclusion criteria.21,24–36 The selection and screening process is presented in detail (see Figure 1).

Characteristics of Studies

Primary Resistance to Amoxicillin

Among patients (n=4218) previously never taken the treatment regimen, no resistance was reported in Europe and North America for AMX. In contrast to this, higher resistance rate was reported from Africa (17.7%). Asian and Latin American studies also reported comparable resistance pattern of 3.9% and 4.4%, respectively. A study conducted in Egypt, among 46 study participants almost half of them were non-susceptible to AMX. Similar to this, a study conducted in Nigeria and Peru reported one-third of *H. pylori* positive patients were non-susceptible. But, no resistances were seen in Morocco, Poland, Turkey, America, Canada and Nepal.

Primary Resistance to Clarithromycin

Clarithromycin (CLR) is a Macrolide derivative used in the treatment of *H. pylori* eradication. CLR resistance has shown an association in predicting treatment failure of *H. pylori* eradication therapy.22Comparable resistance rate was reported in Europe (31.3%) and Asia (30.9%) respectively. Within this the bacterial non-susceptibility rate was reported as 26.7% in Africa. Low rate of resistance was obtained in North America (18.5%) and South America (19.4) in comparison to other continents. Above half patients were non-susceptible in Poland, Egypt and China. *H. pylori* resistance of CLR has significantly increased in 2009–10 and 2013–14 as a study reported from china.21

---

Figure 1 PRISMA flow chart representation showing the overall searching and article selection process of a study *Helicobacter pylori* primary resistance pattern to antibiotics. Note: Adapted from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. [https://doi.org/10.1371/journal.pmed.1000097](https://doi.org/10.1371/journal.pmed.1000097).
Primary Resistance to Metronidazole
Metronidazole (MTR) is an alternative for penicillin-allergic candidates during *H. pylori* eradication therapy. Unlike De Francesco et al, however, a substantial treatment and higher rate of resistance was reported in Nigeria, Nepal, China, Peru and Poland with a prevalence rate of 99.1%, 88.1%, 66.8%, 61.8% and 56.7%, respectively.

Primary Resistance to Levofloxacin
It is a promising Fluoroquinolones derivative used in the eradication of *H. pylori* infection. However, a substantial prevalence of resistance was observed especially in North America and Asia; 29.2% and 29.9%, respectively. In addition to this, indispensable primary resistance rate was reported in other continents; Europe (13.0%), South America (7.2%), and Africa (5.7%) in descending order.

Primary Dual and Multiple Antibiotic Resistances
A higher multiple antibiotic resistance rate was reported from Turkey (n=98) CLR-MTR-LVX 18.1% and out of 110 American *H. pylori* positive patients, 1.8% were resistant for CLR-MTR-LVX and for CLR-MTR, 5.5% for CLR-LVX and MTR-LVX. In Poland among 67 participants 32.5%, 1.5%, and 4.5% individuals were non-susceptible for CLR-MTR-LVX and for CLR-MTR, 5.5% for CLR-LVX and MTR-LVX, respectively. Above the multiple drug resistance, a higher dual resistance rate was also seen in Turkey (n=98); 45.4% and 27.2% to CLR-MTR and to CLR-LVX resistance rate were reported, respectively. In addition, dual resistance pattern of 1.8% was reported to MTR/CLR in Singapore. About 10.5% (n=76) of Peruvian patients were resistant for AMX/CLR which are parts of the standard triple therapy regimen (Table 1).

Overall Resistance
From a total of 14 studies retrieved with a total of 4218 study participants of *H. pylori* positive patients, the overall pooled primary resistance was found; 4.55% at 95% CI: 3.96–5.22% for AMX, 27.22% at 95% CI: 25.89–28.58% for CLR, 39.66% at 95% CI: 38.20–41.15% for MTR, and 22.48% at 95% CI: 21.24–23.76% for LVX. These studies were from different continents including from Europe, North America, South America, Asia and Africa. These studies had used different methods of testing antibiotic susceptibility (Table 2).

Discussion
The treatment success of *H. pylori* eradication achieved by first-line treatment with a proton pump inhibitor, CLR and AMX have decreased to 70–85% due to increasing CLR resistance. Unlike De Francesco et al consideration where improved knowledge in drug resistance strategies can result in better infection control, the safe and effective way of bacterial infection prevention and control seems difficult to touch.

The present study found higher resistance rate of CLR recorded in Europe, Asia and Africa. In addition, highest rate of non-susceptibility was seen in Asia for MTR and LVX. Concurrent to this, other worldwide systematic review

Table 1 Primary Resistance Pattern of *Helicobacter pylori* to Antibiotics Across Different Countries 2015–2017

| Author(s) and Year | Country | No. of Participants (n) | Study Period | Prevalence of Primary Antibiotic Resistance |
|--------------------|---------|-------------------------|--------------|-------------------------------------------|
| Zhang et al 2015*24 | China   | 375                     | 2009–10     | 0.067(0.0478–0.0996) 0.399(0.3517–0.4504) 0.668(0.6202–0.7150) 0.345(0.3003–0.3962) |
| Zhang et al 2015*24 | China   | 950                     | 2013–14     | 0.044(0.0329–0.0592) 0.526(0.4945–0.5579) 0.638(0.6079–0.6689) 0.548(0.5166–0.5799) |
| Caliskan et al 2015*24 | Turkey  | 98                      | 2012–13     | 0                       0.367(0.2786–0.4661) 0.355(0.2693–0.4557) 0.295(0.2146–0.3936) |
| Ferenc et al 2017*25 | Poland  | 67                      | 2011–13     | 0                       0.352(0.4336–0.6652) 0.567(0.4841–0.6790) 0.059(0.0235–0.1437) |
| Ang et al 2016*26   | Singapore| 170                    | 2012–14     | 0.041(0.0201–0.0825) 0.171(0.1215–0.2632) 0.488(0.4636–0.5570) 0.147(0.1016–0.2081) |
| Boehne et al 2017*27 | Peru    | 76                      | 2011–13     | 0.329(0.2338–0.4406) 0.355(0.2550–0.4674) 0.618(0.5060–0.7194) 0.539(0.4282–0.6469) |
| Tamayo et al 2017*28 | Spain   | 91                      | 2014–15     | NA                      0.077(0.0378–0.1504) NA                       NA                       |
| Shtota et al 2015*29 | America | 110                     | 2009–13     | 0.0                       0.145(0.0916–0.2233) 0.173(0.1135–0.2541) 0.291(0.2142–0.3817) |
| Eng et al 2015*30   | Canada  | 20                      | 2012–13     | 0.40(0.2188–0.6134) 0.169(0.1388–0.2051) 0.35(0.1812–0.5671) 0.30(0.1455–0.5190) |
| Sanchys et al 2016*31 | Brazil  | 490                     | 2012–15     | NA                      0.169(0.1388–0.2051) NA                       NA                       |
| Mitahussurur et al 2016*32 | Nepal  | 42                      | 2012        | 0.214(0.1171–0.3594) 0.312(0.2005–0.4166) 0.257(0.2351–0.2809) 0.429(0.2912–0.5779) |
| Liu et al 2015*33   | Taiwan  | 1395                    | 2000–12     | 0.023(0.0169–0.0330) 0.112(0.0970–0.1302) 0.257(0.2351–0.2809) 0.429(0.2912–0.5779) |
| Bouihet et al 2016*34 | Morocco| 177                     | 2014        | 0                       0.254(0.1958–0.3231) 0.401(0.3316–0.4747) 0.107(0.0698–0.1616) |
| Zeki et al 2016*35  | Egypt   | 46                      | 2014–15     | 0.478(0.3412–0.6186) 0.608(0.4646–0.7361) 0.217(0.1226–0.3557) NA                       |
| Harrison et al 2017*36 | Nigeria| 111                     | 2010–13     | 0.333(0.2525–0.4253) 0.144(0.0907–0.2214) 0.991(0.9507–0.9984) NA                       |

Abbreviations: AMX, amoxicillin; CLR, clarithromycin; LVX, levofloxacin; MTR, metronidazole; NA, not analyzed.
Table 2 Overall Primary Resistance Pattern of *Helicobacter pylori* to Antibiotics in Adult Population Across Different Continents 2015–2017

| Country          | No. of Participants | Overall Prevalence of Primary Antibiotic Resistance |
|------------------|---------------------|-----------------------------------------------------|
|                  |                     | AMX | CLR | MTR | LVX |
| Europe           | 256                 | 0   | 0.3125 (0.2588–0.3717) | 0.2852 (0.2333–0.3433) | 0.1289 (0.0933–0.1755) |
| North America    | 130                 | 0   | 0.1850 (0.1273–0.2600) | 0.2000 (0.1403–0.2769) | 0.2923 (0.2210–0.3756) |
| South America    | 566                 | 0.0442 (0.0301–0.0644) | 0.1943 (0.1639–0.2290) | 0.0830 (0.0630–0.1087) | 0.0724 (0.0538–0.0968) |
| Asia             | 2732                | 0.0395 (0.0328–0.0478) | 0.3093 (0.2922–0.3269) | 0.4890 (0.4703–0.5078) | 0.2990 (0.2822–0.3165) |
| Africa           | 334                 | 0.1766 (0.1395–0.2212) | 0.2665 (0.2219–0.3163) | 0.5719 (0.5183–0.6238) | 0.0569 (0.0367–0.0871) |
| Overall          | 4218                | 0.0455 (0.0396–0.0522) | 0.2722 (0.2589–0.2858) | 0.3966 (0.3820–0.4115) | 0.2248 (0.2124–0.2376) |

reported, the overall rate of *H. pylori* antibiotic resistance was found 11.2% to AMX, 17.2% to CLR, 26.7% to MTR, and 16.2% to LVX. The prevalence rate of CLR, MTR and LVX resistance was significantly increased from Europe to Asia, Northern America and Africa. This might be due to irrational use of antibiotics. Similarly, other study also addressed the rate of *H. pylori* antibiotic resistance were 14.7% to AMX, 19.7% to CLR, 47.2% to MTR, and 18.9% to LVX. The prevalence rate of MTR and AMX resistance was higher in Africa, while CLR and LVX resistance was higher in North America and Asia, respectively. Compared to these studies, the primary resistance rate towards CLR substantially increased from 17.2% to 19.7% to 27.2%. LVX resistance was also increased from 16.2% to 22.5%. Despite the over consumption of AMX and MTR the frequency of non-susceptibility rate of these antibiotics was found decreased. This was in contrary to previous studies. This might be due to the recent implementation of antimicrobial stewardship and rational antimicrobial practice awareness creation. However, even in the recent implementation of the programs the other above mentioned antibiotics resistance rate is substantially increased which necessities other studies to be undertaken.

Country specific systematic review studies reported 16.0%, 22.4%, 61.6%, and 5.3% in Iran; 9.7%, 24.8%, 33.7%, and 23.8% in Turkey; 4%, 12%, and 53% in Latin America (no for LVX); 3.1%, 28.9%, 63.8%, and 28.0%, in China to AMX, CLR, MTR and LVX, respectively. The resistance pattern for MTR and LVX was diffused and higher especially to MTR. AMX resistance in Latin America and China was comparable however Turkish and Iranian reviews reported double and almost four times higher from the present study. This shows the antibiotic susceptibility pattern of *H. pylori* could not be predicted arbitrary in any country mandating that implementation of local drug susceptibility surveillance program and appropriate or rational prescribing and use of antibiotics is necessary.

Individual and dual antibiotic resistance significantly influences the successful eradication of the bacterial infection. The Maastricht V 2016 guideline report articulates resistance to CLR affect the efficacy of both sequential and triple treatment methods and resistance to MTR affects the treatment success by sequential therapy. Moreover, the report also had reported resistance to CLR and MTR affects the efficacy of sequential, hybrid and concomitant therapy of *H. pylori* eradication treatment protocols. According to this empirical triple therapy is discouraged. When the resistance of *H. pylori* is greater than 15% towards CLR at the specified area the treatment should be based on susceptibility pattern to other antibiotics.

Multi-resistant strains of *H. pylori* result in life-long infection that might lead to death. With the reserved treatment alternatives, a study conducted by Olleik et al on temporin-SH and its analogs resulted in good activity against resistant strains of *H. pylori* which should be taken as promising treatment alternatives for the eradication of resistant *H. pylori* infection.

Appropriate surveillance programs, improved antimicrobial regulations and increased public awareness to region-specific resistance rate of *H. pylori* isolates are possible mechanisms of prevention for *H. pylori* associated drug resistance. Therefore, drug susceptibility result of these antibiotics is necessary to select the appropriate drug for the successful eradication of the infection. This fosters rational drug prescribing practice improve patient treatment outcome and avoid unnecessary medical and nonmedical expenditure.

### Conclusion

The primary antibiotic resistance of *H. pylori* is increasing worldwide. The overall resistance rate was found to be 4.55% at 95% CI (3.96–5.22) for amoxicillin; 27.22% at 95% CI (25.89–28.58) for clarithromycin; 39.66% at 95% CI (37.3–42.02) for metronidazole; 43.67% at 95% CI (41.17–46.17) for levofloxacin; 47.34% at 95% CI (44.73–49.94) for clarithromycin and metronidazole combination. This shows the urgent need for the implementation of local drug susceptibility surveillance program and appropriate or rational prescribing and use of antibiotics is necessary.
CI (38.20–41.15) for metronidazole; and 22.48% at 95% CI (21.24–23.76) for levofloxacin. The antibiotic susceptibility pattern of the *H. pylori* could not be predicted arbitrary in any country mandating that implementation of local drug susceptibility surveillance program and appropriate or rational prescribing and use of antibiotics as necessary.

**Abbreviations**

AMX, amoxicillin; CLR, clarithromycin; *H. pylori*, *Helicobacter pylori*; LVX, levofloxacin; MTR, metronida-zole; NHS, National Institute for Health research.

**Data Sharing Statement**

The datasets used for this study should be accessed from the corresponding author on reasonable request.

**Author Contributions**

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Disclosure**

The authors declare they have no conflicts of interest in this work.

**References**

1. CDC. *Helicobacter Pylori: Fact Sheet for Health Care Providers*. Department of Health and Human Services. 1–4, 1998.
2. Blanchard TG, Nedrud JG. Laboratory maintenance of *Helicobacter* species. *Curr Protoc Microbiol*. 2012;24:SB.1.1–SB.1.19. doi:10.1002/9780471729259.mc08061s24
3. Smith SM, O’morain C, Menamara D. Antimicrobial susceptibility testing for *Helicobacter pylori* in times of increasing antibiotic resistance. *World J Gastroenterol*. 2014;20:9912. doi:10.3748/wjg.v20.i29.9912
4. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol*. 2007;102:1808. doi:10.1111/j.1572-0241.2007.01393.x
5. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of *Helicobacter pylori* infection. *Helicobacter*. 2014;19:1–5. doi:10.1111/hel.12165
6. Fuccio L, Laterza L, Zagari RM, Cennamo V, Grilli D, Bazzoli F. Treatment of *Helicobacter pylori* infection. *BMJ*. 2008;15:337.
7. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of *Helicobacter pylori* infection. *Am J Gastroenterol*. 2017;112:212–239. doi:10.1038/ajg.2016.563
8. Malfertheiner P, Megraud F, O’morain CA, et al. Management of *Helicobacter pylori* infection, the Maastricht IV/Florence consensus report. *Gut*. 2012;61:646–664. doi:10.1136/gutjnl-2012-302084
9. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. *Nat Med*. 2004;10:S122–S129. doi:10.1038/nmat145
10. Graham DY, Shiotani A. New concepts of resistance in the treatment of *Helicobacter pylori* infections. *Nat Clin Pract Gastroenterol Hepatol*. 2008;5(6):321–331. doi:10.1038/ncpgasthep1138
11. Nishizawa T, Suzuki H. Mechanisms of *Helicobacter pylori* antibiotic resistance and molecular testing. *Front Mol Biosci*. 2014;1. doi:10.3389/fmolb.2014.00019
12. Wu W, Yang Y, Sun G. Recent insights into antibiotic resistance in *Helicobacter pylori* eradication. *Gastroenterol Res Pract*. 2012;2012:1–8. doi:10.1155/2012/723183
13. De Francesco V, Giorgio F, Hassan C, et al. Worldwide *H pylori* antibiotic resistance: a systematic review. *J Gastrointestin Liver Dis*. 2010;19
14. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of *helicobacter pylori* in Korea from 2003 through 2012. *Helicobacter*. 2013;18:206–214. doi:10.1111/hel.12031
15. De Francesco V, Giorgio F, Ierardi E, et al. Primary clarithromycin resistance in *Helicobacter pylori*: the multicentric Italian clarithromycin resistance observational (MICRO) study. *J Gastrointestin Liver Dis*. 2011;20:235–239.
16. Azloubi K, Ayoub N, Al-Sakaji S, Al-Azzam S, Mhaidat N, Masadeh M. Awareness of bacterial resistance among physicians, pharmacists and nurses. *Int J Occup Med Environ Health*. 2009;22:363–372. doi:10.2478/v10001-009-0034-3
17. Owen R. Molecular testing for antibiotic resistance in *Helicobacter pylori*. *Gut*. 2002;50:285–289. doi:10.1136/gut.50.3.285
18. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097
19. Barendretj JI, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. *J Epidemiol Community Health*. 2013;67:974–978. doi:10.1136/jech-2013-203104
20. From available from: https://www.nhbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed May 4, 2020.
21. Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of *Helicobacter pylori* strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. *World J Gastroenterol*. 2015;21:2786. doi:10.3748/wjg.v21.i9.2786
22. Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. High prevalence of clarithromycin-resistant *Helicobacter pylori* strains and risk factors associated with resistance in Madrid, Spain. *J Clin Microbiol*. 2010;48:3703–3707. doi:10.1128/JCM.01444-10
23. Rispo A, Capone P, Castiglione F, Pasquale L, Rea M, Caporaso N. Fluoroquinolone-based protocols for eradication of *Helicobacter pylori*. *World J Gastroenterol*. 2014;20.
24. Caliskan R, Tokman HB, Erzin Y, et al. Antimicrobial resistance of *Helicobacter pylori* strains to five antibiotics, including levofloxacin, in Northwestern Turkey. *Rev Soc Bras Med Trop*. 2015;48:278–284. doi:10.1590/0037-8682-0027-2015
25. Ferenc S, Gnus J, Kościelna M, et al. High antibiotic resistance of *Helicobacter pylori* and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. *Helicobacter*. 2017;22: e12365. doi:10.1111/hel.12365
26. Ang TL, Fock KM, Ang D, Kwek ABE, Teo EK, Dhamodaran S. The changing profile of *Helicobacter pylori* antibiotic resistance in Singapore: a 15 year study. *Helicobacter*. 2016;21:261–265. doi:10.1111/hel.12291
27. Boehnke KF, Valdivieso M, Bussalleu A, et al. Antibiotic resistance among *Helicobacter pylori* clinical isolates in Lima, Peru. *Infect Drug Resist*. 2017;10:85–90. doi:10.2147/IDR.S123798
28. Tamayo E, Montes M, Fernández-Reyes M, et al. Clarithromycin resistance in *Helicobacter pylori* and its molecular determinants in Northern Spain, 2013–2015. *J Glob Antimicrob Resist*. 2017;9:43–46. doi:10.1016/j.jgar.2016.12.019
29. Shiota S, Reddy R, Alsaaraj A, El-Serag HB, Graham DY. Antibiotic resistance of *Helicobacter pylori* among male United States veterans. *Clin Gastroenterol Hepatol*. 2015;13:1616–1624. doi:10.1016/j.cgh.2015.02.005
30. Eng NF, Ybazeta G, Chapman K, et al. Antimicrobial susceptibility of Canadian isolates of *Helicobacter pylori* in Northeastern Ontario. *Can J Infect Dis Med Microbiol*. 2015;26:137–144. doi:10.1155/2015/853287

31. Sanches BS, Martins GM, Lima K, et al. Detection of *Helicobacter pylori* resistance to clarithromycin and fluoroquinolones in Brazil: a national survey. *World J Gastroenterol*. 2016;22:7587. doi:10.3748/wjg.v22.i33.7587

32. Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging *Helicobacter pylori* levofloxacin resistance and novel genetic mutation in Nepal. *BMC Microbiol*. 2016;16:256. doi:10.1186/s12866-016-0873-6

33. Liou JM, Chang CY, Chen MJ, et al. The primary resistance of *Helicobacter pylori* in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors—a nationwide study. *PLoS One*. 2015;10:e0124199. doi:10.1371/journal.pone.0124199

34. Bouihat N, Burucoa C, Benkirane A, et al. *Helicobacter pylori* primary antibiotic resistance in 2015 in morocco: a phenotypic and genotypic prospective and multicenter study. *Microb Drug Resist*. 2016.

35. Zaki MES, Sherif DM, Ali MA, et al. Molecular study of primary clarithromycin resistant *Helicobacter pylori* strains from Egyptian Centre. *Int J Curr Microbiol App Sci*. 2016;5:165–173. doi:10.20546/ijmias.2016.501.014

36. Harrison U, Fowora MA, Seriki AT, et al. *Helicobacter pylori* strains from a Nigerian cohort show divergent antibiotic resistance rates and a uniform pathogenicity profile. *PLoS One*. 2017;12:e0176454. doi:10.1371/journal.pone.0176454

37. Ghotaslou R, Leylabaldo HE, Asl YM. Prevalence of antibiotic resistance in *Helicobacter pylori*: a recent literature review. *World J Methodol*. 2015;5:164. doi:10.5662/wjm.v5.i3.164

38. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis*. 2016;62:1197–1202. doi:10.1093/cid/ciw217

39. Khademi F, Poursina F, Hosseini E, Akbari M, Safaei HG. *Helicobacter pylori* infection in Iran: A systematic review on the antibiotic resistance. *Iran J Basic Med Sci*. 2015;18.

40. Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of *H. pylori* in Turkey: a systematic review. *Helicobacter*. 2016;21:251–260. doi:10.1111/hel.12272

41. Camargo MC, Garcia A, Riquelme A, et al. The problem of *Helicobacter pylori* resistance to antibiotics: a systematic review in Latin America. *Am J Gastroenterol*. 2014;109:485–495. doi:10.1038/ajg.2014.24

42. Hu Y, Zhu Y, Lu NH. Primary antibiotic resistance of *helicobacter pylori* in China. *Dig Dis Sci*. 2017;1–9.

43. Malferttheiner P, Megraud F, O’morain C, et al. Management of *Helicobacter pylori* infection, the Maastricht V/Florence consensus report. *Gut*. 2016;1–25.

44. Acar JF. Consequences of bacterial resistance to antibiotics in medical practice. *Clin Infect Dis*. 1997;24:17–18. doi:10.1093/clinids/24.Supplement_1.S17

45. Friedman ND, Temkin E, Carmeli Y. The negative impact of antibiotic resistance. *Clin Microbiol Infect*. 2016;22:416–422. doi:10.1016/j.cmi.2015.12.002

46. Miftahussurur M, Waskito LA, Syam AF, et al. Alternative eradication regimens for *Helicobacter pylori* infection in Indonesian regions with high metronidazole and levofloxacin resistance. *Infect Drug Resist*. 2019;12:345. doi:10.2147/IDR.S187063

47. Olleik H, Baydoun E, Perrier J, et al. Temporin-SHa and its analogs as potential candidates for the treatment of *helicobacter pylori*. *Biomolecules*. 2019;9:598. doi:10.3390/biom9100598

48. Shmuel H, Donniz N, Yahav J. Regional antibiotic resistance of *helicobacter pylori*. *JSM Gastroenterol Hepatol*. 2016;4:1074.

49. Seck A, Burucoa C, Dia D, et al. Primary antibiotic resistance and associated mechanisms in *Helicobacter pylori* isolates from Senegalese patients. *Ann Clin Microbiol Antimicrob*. 2013;12:3. doi:10.1186/1476-0711-12-3